Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies Inc. reports developments as a commercial-stage pharmaceutical company focused on infectious-disease countermeasures, with a primary focus on orthopoxviruses. Its recurring updates center on TPOXX (tecovirimat), including oral and IV product sales, deliveries to large institutional customers and international governments, Strategic National Stockpile activity, and procurement contracts.
Company news also covers quarterly and annual results, research and development revenue, BARDA 19C development funding for pediatric and manufacturing activities, regulatory developments for tecovirimat indications, business update calls, and capital actions such as special cash dividends on common stock.
SIGA Technologies, a pharmaceutical company, will host a business update call on May 7, 2024, following the release of their first-quarter financial results. The call will feature the CEO and CFO and will be available via webcast and conference call. Participants can access the call through the company's website or by dialing in. A replay will be available for two weeks.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.